The 7th Neuroimmunology Drug Development Summit takes place in Boston, US on February 25-27.
As a leading provider of neurobiology in vitro research services, Cellectricon is proud to be a partner of the summit. We are very much looking forward to joining other industry experts in the discussion on approaches for discovering and developing therapies for treatment of underlying neuroinflammation in neurological disorders.
At the meeting Johan Pihl, CSO, will give a presentation on February 26 highlighting our work to establish in vitro models for neuroinflammation research and drug discovery:
A Translationally Relevant Systems Biology Platform for Neuroinflammation
- Outlining development of a chimeric culture system where human iPSC microglia robustly and appropriately respond to inflammatory stimuli
- Platform recapitulates neuroinflammation systems biology endpoints amenable for target validation and compound characterization
- Further refinement of platform informed by human biomarker signature of neurodegenerative disease
If you are interested in learning more about the Neuroinflammation Service Module or Cellectricon’s drug discovery services, please reach out to us.
Paul Karila
CBO
Meet us at the Neuroimmunology drug development summit!
We are looking forward to taking part in this year’s meeting and for the opportunity to provide an update on our service module for neuroinflammation research to clients and new contacts. Get in touch if you are interested in setting up a meeting!